Anthem Biosciences (ANTHEM) Q2 25/26 earnings summary

Executive summary

• H1 FY2026 consolidated revenue reached ₹10,902.36 million, with strong CRDMO growth and EBITDA margin of 41.4%.

• PAT for H1 FY2026 was ₹3,092.18 million, with a PAT margin of 26.6%.

• Net cash position improved to ₹9,934 million as of September 30, 2025.

• Management remains confident in sustaining growth and long-term value creation.

• Unaudited financials for H1 FY26 were approved and reviewed by the Board and Audit Committee.

Financial highlights

• H1 FY26 revenue from operations was ₹10,902.36 million, up 26.3% year-over-year.

• H1 FY26 EBITDA was ₹4,800 million, with a margin of 41.4%.

• H1 FY26 PAT was ₹3,092.18 million, with a margin of 26.6%.

• Basic EPS (consolidated) for H1 FY26 was ₹5.52.

• Net cash from operating activities (consolidated) for H1 FY26 was ₹4,025.17 million.

Outlook and guidance

• Specialty ingredients expected to recover in H2 as new capacity comes online.

• EBITDA margins are expected to remain at the upper end of the 36–37% guidance for the full year.

• Management targets maintaining a 20% CAGR, with quarter-to-quarter variations possible.

• IPO proceeds and ESOP allotments have strengthened the equity base.

• Management expresses confidence in sustaining growth momentum and delivering long-term stakeholder value.